FDA adds boldest warning to most widely used painkillers
WASHINGTON — Federal health regulators will add their strongest warning labels to the most widely prescribed painkillers, part of a multipronged government campaign to stem an epidemic of abuse and death tied to drugs such as Vicodin and Percocet.
The Food and Drug Administration announced Tuesday plans to add a boxed warning — the most serious type — to all immediate-release opioid painkillers, including about 175 branded and generic drugs.
Those medications, which often combine oxycodone with lower-grade medications, are among the most commonly used drugs in the United States and account for 90 percent of all opioid painkillers prescribed.
Roughly three years ago the FDA added similar warnings to long-acting opioid drugs such as OxyContin, which slowly release their doses over 12 hours or more. Now both immediate and extended-release formulations will highlight the risks of addiction, abuse, overdose, and death.
The long-awaited changes come as federal and state officials struggle to curb a wave of overdoses fueled by the overprescribing of medications and a steady supply of cheap heroin.
‘‘We’re at a time when the unfathomable tragedies resulting from addiction, overdose, and death have become one of the most urgent and devastating public health crises facing our country,’’ FDA Commissioner Dr. Robert Califf said on a call with reporters. ‘‘I can’t stress enough how critical it is for prescribers to have the most current information.’’
But lawmakers from states that have been ravaged by opioid addiction said such labeling changes have ‘‘done little’’ to help their communities.
‘‘Unfortunately, it has taken FDA far too long to address the grave risks of these drugs that have claimed the lives of thousands this year alone,’’ said Senator Edward Markey, Democrat of Massachusetts.
Opioids are a class of powerful and highly addictive drugs that include prescription drugs like codeine and hydrocodone as well as illegal narcotics, such as heroin.
Deaths linked to misuse and abuse of prescription opioids climbed to 19,000 in 2014, the highest figure on record, according to the Centers for Disease Control and Prevention. Heroin and opioid painkillers combined caused 28,650 fatal overdoses.
Doctors are not required to follow the FDA’s instructions on drug labels, though they are often used as prescribing guidelines by hospitals, medical groups, and insurers.
Critics of the FDA, including Physicians for Responsible Opioid Prescribing, called on the agency to add such warnings years ago.
‘‘The main driver of our opioid epidemic is addiction, and the immediate-release products are just as addictive,’’ said the group’s founder, Dr. Andrew Kolodny, an addiction therapist with Phoenix House, a network of rehabilitation clinics.
The new FDA label will specify that the drugs should be used only when other medications and alternative therapies cannot control patients’ pain.
‘‘This new indication, once finalized, will remind prescribers that immediate-release opioids are also powerful drugs with important safety concerns,’’ said Dr. Doug Throckmorton, a deputy director in the FDA’s drug center.
Throckmorton said the agency’s 2013 labeling change focused on long-acting drugs such as OxyContin because they represented a ‘‘disproportionate risk’’ to patients, since they contain larger opioid levels.
Government officials have tried a variety of approaches to tackling painkiller abuse in recent years. The FDA previously restricted combination pills such as Vicodin to limit refills and who can prescribe them. States like Florida and New York have cracked down on ‘‘pill mills’’ using databases to monitor what doctors are prescribing.
The Obama administration has asked Congress to provide $1.1 billion to combat opioid addiction. On Tuesday, the White House sent letters to all 50 governors outlining steps for reducing opioid over-prescribing and enhancing addiction treatment.
The administration’s drug czar praised the move by the FDA and Califf, who was confirmed to lead the agency last month.
‘‘I think we’re very heartened by the new director of the FDA and his enhanced focus on opioid issues,’’ said Michael Botticelli, National Drug Control Policy Director. ‘‘This is an all-of-government effort and clearly the FDA has a key role to play.’’
In addition to the boxed warning, the FDA said it would add new information about the risks of opioid use for pregnant women and their newborns as well as drug interactions with antidepressants and other medications.
“The FDA has taken an important step here,” said Dr. Bruce Psaty, a researcher at the University of Washington in Seattle, who studies drug safety. “This should help improve prescribing practices in the near term.”
He added that it was “another step in the national effort that is reshaping the culture of prescribing in the United States.”
The FDA announcement comes less than a week after the CDC released the first-ever national prescribing guidelines for using opioids. The agency said primary care doctors should only turn to opioids after considering physical therapy, over-the-counter medications, counseling and other methods for treating chronic pain.
Material from The New York Times was used in this report.